Morning Briefing
Summaries of health policy coverage from major news organizations
High Cost Of Potent Hepatitis Drug Presents Challenges Across The U.S.
Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over its high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
